Organizations that can generate and apply high-quality, clinically grounded evidence will be better positioned to close the gap between what is proven in trials and what is achieved in practice.
The post Why Real-World Evidence Is Becoming the Missing Link Between Innovation and Patient Care in Oncology appeared first on MedCity News.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
